New smart chemo targets HER-2 cancers in early trial
Disease control
Recruiting now
This early-phase study tests a new drug, HF158K1, which delivers chemotherapy directly to cancer cells that have a protein called HER-2. The trial includes about 84 adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check the…
Phase: PHASE1 • Sponsor: HighField Biopharmaceuticals Corporation • Aim: Disease control
Last updated Apr 29, 2026 15:15 UTC